Valuation: Genome & Company

Market Cap 149B 104M 90.06M 83.82M 76.96M 145M 9.89B 148M 988M 388M 4.92B 389M 381M 16.51B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 131B 91.17M 79.26M 73.77M 67.73M 128M 8.7B 130M 870M 341M 4.33B 342M 335M 14.53B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
82.97%
Yield 2024 *
-
Yield 2025 -
04-13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
04-03 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
03-13 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
22/09/25 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
21/08/25 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
10/07/25 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
28/04/25 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
24/04/25 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
24/04/25 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
24/04/25 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
19/07/24 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
17/07/24 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24/01/24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day+9.70%
1 week-12.06%
1 month-15.03%
3 months-53.54%
6 months-61.90%
Current year-52.33%
1 week 2,975
Extreme 2975
3,990
1 month 2,975
Extreme 2975
4,545
Current year 2,975
Extreme 2975
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 24/09/2015
Chief Executive Officer 55 24/09/2015
Director TitleAgeSince
Director/Board Member 55 24/09/2015
Director/Board Member 53 24/09/2015
Director/Board Member 62 -
Date Insider Type Main position Quantity % Market Cap.
09/05/25 Don

Chief Executive Officer

100,000 0.3217%
09/05/25 Free

Director

40,000 0.1287%
09/05/25 Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
+9.70%-12.06%+18.20%-52.29% 104M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -0.38%-0.42%+54.85%+85.99% 25.05B
Weighted average by Cap. -1.59%+2.03%+76.84%+128.02%

Financials

2024 2025
Net sales 27.74B 19.3M 16.78M 15.62M 14.34M 27.08M 1.84B 27.5M 184M 72.25M 917M 72.49M 70.9M 3.08B 24.59B 17.11M 14.87M 13.84M 12.71M 24M 1.63B 24.37M 163M 64.03M 813M 64.24M 62.83M 2.73B
Net income -20.11B -13.99M -12.16M -11.32M -10.39M -19.63M -1.34B -19.93M -133M -52.38M -665M -52.55M -51.4M -2.23B -6.43B -4.47M -3.89M -3.62M -3.32M -6.27M -427M -6.37M -42.65M -16.74M -213M -16.8M -16.43M -713M
Net Debt -48.91B -34.03M -29.58M -27.53M -25.28M -47.73M -3.25B -48.47M -325M -127M -1.62B -128M -125M -5.42B -17.86B -12.43M -10.8M -10.06M -9.23M -17.43M -1.19B -17.7M -119M -46.52M -591M -46.67M -45.65M -1.98B
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
31/07/26 ₩3,280.00 +9.70% 619,637
30/07/26 ₩2,990.00 -3.55% 399,917
29/07/26 ₩3,100.00 -13.04% 995,620
28/07/26 ₩3,565.00 -6.18% 220,374
27/07/26 ₩3,800.00 +1.88% 148,913
  1. Stock Market
  2. Stocks
  3. A314130 Stock